drugset / Trial / NCT02228681

Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer

NCT02228681

Phase 2 Completed 74 enrolled GOG Foundation Novartis Pharmaceuticals · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study is to evaluate the effectiveness of the combination of the drugs Everolimus and Letrozole compared to Tamoxifen and Medroxyprogesterone acetate in treating endometrial cancer and to determine the types and severity of side effects caused by treatment with these drug combinations.

Timeline

Start
2015-05-21
Primary completion
2018-01
Completion
2024-08-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule 10 mg Oral
Subject Letrozole Other / unclassified 2.5 mg Oral
Comparator Tamoxifen Small molecule 20 mg Oral
Comparator medroxyprogesterone acetate Other / unclassified 200 mg Oral

Indications